SOURCE: MorphoSys AG

April 09, 2010 11:08 ET

MorphoSys AG (DE) - Announcement of the Convening of the General Meeting in Munich/Germany on 21/05/2010 According to Article 121 AktG (German Stock Companies Act) With the Objective of Europe-Wide Distribution

MARTINSRIED, GERMANY--(Marketwire - April 9, 2010) -


MorphoSys AG
Martinsried/Planegg
Wertpapierkennnummer 663200
ISIN:DE0006632003

Invitation to the Annual Shareholders' Meeting 2010

We hereby invite the shareholders of our Company to the Annual Shareholders' Meeting which is taking place on Friday, May 21, 2010 at 10:30 a.m., in the Conference Centre Munich, Hanns-Seidel-Stiftung, Lazarettstraße 33, 80636 Munich.

Agenda

1. Presentation of the confirmed annual financial statements as of
   December 31, 2009, the management report together with the
   consolidated financial statements, the consolidated management report
   and the report of the Supervisory Board for the business year 2009 and
   the statement of the Board of Management to the items pursuant to § §
   289 para. 4, 315 para. 4 HGB
2. Formal approval on behalf of the Board of Management
3. Formal approval on behalf of the Supervisory Board
4. Appointment of the auditors for the business year 2010
5. Resolution on the approval of the remuneration scheme of Members of the
   Board of Management
6. Resolution on the authorization to purchase and use treasury stock and
   on the exclusion of subscription rights
7. Resolution on amendments of the articles of association in accordance
   with the Act Implementing the Shareholders' Rights Directive (ARUG)
8. Partial deletion of the conditional capital 2003-II, amendment of the
   Articles
9. Compensation of the Supervisory Board

Please find the full text of the announcement here: http://www.morphosys.com/agm

About MorphoSys:

MorphoSys is an independent biotechnology company that develops novel antibodies for therapeutic, diagnostic and research applications. The Company's HuCAL technology is one of the most powerful methods available for generating fully human antibodies. By successfully applying this and other proprietary technologies, MorphoSys has become a leader in the field of therapeutic antibodies, one of the fastest-growing drug classes in human health-care. Through its alliances with some of the world's leading pharmaceutical companies, MorphoSys has created a pipeline of more than 60 drug candidates. The Company is expanding its drug pipeline by adding new partnered programs, and by building a portfolio of fully-owned therapeutic antibodies. For its proprietary portfolio, the Company is focused on the areas of oncology and inflammation. Its most advanced program MOR103, a first-in-class, fully human antibody against GM-CSF, is currently tested in a Phase Ib/IIa trial in rheumatoid arthritis patients. Via its business unit AbD Serotec, MorphoSys is expanding the reach of its technologies in the diagnostics and research markets. MorphoSys is headquartered in Munich, Germany and listed on the Frankfurt Stock Exchange under the symbol "MOR". For further information, visit http://www.morphosys.com/

Contact Information

  • MorphoSys AG
    Dr. Claudia Gutjahr-Löser
    Head of Corporate Communications & IR
    Tel: +49 (0) 89 / 899 27-122